1. Inicio
  2. Publicaciones
  3. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort.

ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Vicente-Baz D
  • Paredes A
  • Morán T
  • Massuti B
  • Reguart N
  • Álvarez R
  • Insa A
  • Artal Á
  • Esteban E
  • García-Campelo R
  • Ortega-Granados AL
  • Diz P
  • González-Larriba JL
  • Terrasa J
  • de Las Peñas R
  • Rodríguez-Abreu D
  • Callejo Á
  • Márquez G
  • Provencio M

Grupos

Abstract

Osimertinib has proven efficacy in EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) patients; however, its benefits have not been evaluated in a real-world setting.

Datos de la publicación

ISSN/ISSNe:
1699-8855, 1988-561X

REVISTA ESPANOLA DE PATOLOGIA  Elsevier BV

Tipo:
Article
Páginas:
140-148
PubMed:
32650965
Factor de Impacto:
0,129 SCImago ℠
Cuartil:
Q4 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Cáncer de pulmón no microcítico, EGFR T790M mutation, Inhibidor de quinasa tirosina, Mutación de EGFR T790M, Non-small cell lung cancer, Osimertinib, Tyrosine kinase inhibitor

Cita

Compartir